A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Novartis
University of Chicago
Cho Pharma Inc.
National Institutes of Health Clinical Center (CC)